Polyphenolic antioxidants mimic the effects of 1,4-dihydropyridines on neurotensin receptor function in PC3 cells

被引:15
作者
Carraway, RE
Hassan, S
Cochrane, DE
机构
[1] Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA
[2] Tufts Univ, Dept Biol, Medford, MA 02155 USA
关键词
D O I
10.1124/jpet.103.060442
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study aimed to determine the mechanism(s) by which 1,4-dihydropyridine Ca2+ channel blockers (DHPs) enhance the binding of neurotensin (NT) to prostate cancer PC3 cells and inhibit NT-induced inositol phosphate formation. Earlier work indicated that these effects, which involved the G protein-coupled NT receptor NTR1, were indirect and required cellular metabolism or architecture. At the micromolar concentrations used, DHPs can block voltage-sensitive and store-operated Ca2+ channels, K+ channels, and Na+ channels, and can inhibit lipid peroxidation. By varying [Ca2+] and testing the effects of stimulators and inhibitors of Ca2+ influx and internal Ca2+ release, we determined that although DHPs may have inhibited inositol phosphate formation partly by blocking Ca2+ influx, the effect on NT binding was Ca2+-independent. By varying [K+] and [Na+], we showed that these ions did not contribute to either effect. For a series of DHPs, the activity order for effects on NTR1 function followed that for antioxidant ability. Antioxidant polyphenols (luteolin and resveratrol) mimicked the effects of DHPs and showed structural similarity to DHPs. Antioxidants with equal redox ability, but without structural similarity to DHPs (such as alpha-tocopherol, riboflavin, and N-acetyl-cysteine) were without effect. A flavoprotein oxidase inhibitor (diphenylene iodonium) and a hydroxy radical scavenger (butylated hydroxy anisole) also displayed the effects of DHPs. In conclusion, DHPs indirectly alter NTR1 function in live cells by a mechanism that depends on the drug's ability to donate hydrogen but does not simply involve sulfhydryl reduction.
引用
收藏
页码:92 / 101
页数:10
相关论文
共 45 条
[1]   Epidermal growth factor (EGF)-induced generation of hydrogen peroxide - Role in EGF receptor-mediated tyrosine phosphorylation [J].
Bae, YS ;
Kang, SW ;
Seo, MS ;
Baines, IC ;
Tekle, E ;
Chock, PB ;
Rhee, SG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (01) :217-221
[2]   Neurotensin modulates the amplitude and frequency of voltage-activated Ca2+ currents in frog pituitary melanotrophs:: implication of the inositol triphosphate/protein kinase C pathway [J].
Belmeguenai, A ;
Leprince, J ;
Tonon, MC ;
Vaudry, H ;
Louiset, E .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2002, 16 (10) :1907-1916
[3]   NADPH oxidase promotes NF-κB activation and proliferation in human airway smooth muscle [J].
Brar, SS ;
Kennedy, TP ;
Sturrock, AB ;
Huecksteadt, TP ;
Quinn, MT ;
Murphy, TM ;
Chitano, P ;
Hoidal, JR .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2002, 282 (04) :L782-L795
[4]   Regulation of cell apoptosis by protein kinase c δ [J].
Brodie, C ;
Blumberg, PM .
APOPTOSIS, 2003, 8 (01) :19-27
[5]  
CARRAWAY R, 1976, J BIOL CHEM, V251, P7045
[6]   EFFECTS OF GTP ANALOGS AND METAL-IONS ON THE BINDING OF NEUROTENSIN TO PORCINE BRAIN MEMBRANES [J].
CARRAWAY, RE ;
MITRA, SP ;
HONEYMAN, TW .
PEPTIDES, 1993, 14 (01) :37-45
[7]   Ca2+ channel blockers enhance neurotensin (NT) binding and inhibit NT-induced inositol phosphate formation in prostate cancer PC3 cells [J].
Carraway, RE ;
Gui, XY ;
Cochrane, DE .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (02) :640-650
[8]   Structure and regulation of voltage-gated Ca2+ channels [J].
Catterall, WA .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2000, 16 :521-555
[9]   Direct binding of G-protein beta gamma complex to voltage-dependent calcium channels [J].
DeWaard, M ;
Liu, HY ;
Walker, D ;
Scott, VES ;
Gurnett, CA ;
Campbell, KP .
NATURE, 1997, 385 (6615) :446-450
[10]   Antioxidant effects of 1,4-dihydropyridine and nitroso aryl derivatives on the Fe+3/ascorbate-stimulated lipid peroxidation in rat brain slices [J].
Díaz-Araya, G ;
Godoy, L ;
Naranjo, L ;
Squella, JA ;
Letelier, ME ;
Núñez-Vergara, L .
GENERAL PHARMACOLOGY, 1998, 31 (03) :385-391